Yoo L I, Mooney M, Puglielli M T, Speck S H
Department of Pathology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
J Virol. 1997 Dec;71(12):9134-42. doi: 10.1128/JVI.71.12.9134-9142.1997.
During Epstein-Barr virus (EBV) latent infection of B lymphocytes in vitro, six viral nuclear antigens (EBNAs) are expressed from one of two promoters, Cp or Wp, whose activities have previously been shown to be mutually exclusive in established lymphoblastoid cell lines. Initially after infection, the EBNA genes are transcribed from Wp, which is present in multiples copies within the major internal repeat of EBV. Approximately 48 to 72 h postinfection, Wp is downregulated, with a corresponding increase in transcription from Cp. An EBNA2-responsive enhancer exists upstream of Cp, and a role for EBNA2 in the induction of Cp activity during the establishment of viral latency has previously been proposed (Woisetschlaeger et al., Proc. Natl. Acad. Sci. USA 87:1725-1729, 1991). To critically assess the potential role for this enhancer region in determining relative usage of Cp and Wp, an EBNA2 enhancer deletion mutant virus was generated. Lymphoblastoid cell lines were screened by PCR and Southern blotting for the presence of mutant virus harboring the EBNA2 enhancer deletion. A quantitative S1 nuclease protection assay was developed to allow comparison of relative Cp and Wp activities for the cell lines containing mutant virus and those of the wild-type recombinants which lacked the enhancer deletion. In general, the wild-type recombinants had higher levels of Cp-initiated transcripts than Wp-initiated transcripts. In contrast, the Cp EBNA2 enhancer deletion mutants exhibited a strong bias toward Wp activity. Notably, only the first Wp (oriP-proximal Wp; Wp1) appears active in these mutants. S1 nuclease protection assays using a probe which hybridizes to the W2 exon, contained in both Cp- and Wp-initiated transcripts, indicated that the total level of transcription from Cp and Wp remained the same in wild-type and EBNA2 enhancer mutant cell lines. The presence of both Cp and Wp activity in the wild-type recombinants, as well as in newly derived lymphoblastoid cell lines established with the prototype B95.8 virus, demonstrated that Cp and Wp activities are not always mutually exclusive.
在体外爱泼斯坦-巴尔病毒(EBV)对B淋巴细胞的潜伏感染过程中,六种病毒核抗原(EBNAs)由两个启动子之一Cp或Wp表达,此前已证明在已建立的淋巴母细胞系中,这两个启动子的活性相互排斥。感染后最初,EBNA基因从Wp转录,Wp存在于EBV主要内部重复序列中的多个拷贝中。感染后约48至72小时,Wp下调,同时Cp转录相应增加。Cp上游存在一个EBNA2反应增强子,此前有人提出EBNA2在病毒潜伏建立过程中诱导Cp活性方面发挥作用(Woisetschlaeger等人,《美国国家科学院院刊》87:1725 - 1729,1991)。为了严格评估该增强子区域在决定Cp和Wp相对使用方面的潜在作用,构建了一种EBNA2增强子缺失突变病毒。通过PCR和Southern印迹法筛选淋巴母细胞系,以检测携带EBNA2增强子缺失的突变病毒的存在。开发了一种定量S1核酸酶保护测定法,以比较含有突变病毒的细胞系与缺乏增强子缺失的野生型重组体的相对Cp和Wp活性。一般来说,野生型重组体中由Cp起始的转录本水平高于由Wp起始的转录本。相比之下,Cp EBNA2增强子缺失突变体表现出对Wp活性的强烈偏向。值得注意的是,在这些突变体中只有第一个Wp(oriP近端Wp;Wp1)似乎有活性。使用与Cp和Wp起始转录本中都含有的W2外显子杂交的探针进行的S1核酸酶保护测定表明,野生型和EBNA2增强子突变细胞系中Cp和Wp的总转录水平保持不变。野生型重组体以及用原型B95.8病毒建立的新衍生淋巴母细胞系中同时存在Cp和Wp活性,这表明Cp和Wp的活性并不总是相互排斥的。